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Abstract 
Objective 
To examine trends in prenatal diagnosis and pre-implantation diagnosis for Huntington 
disease (HD) in United Kingdom since services commenced. 
Design  
Long term UK wide prospective case record based service evaluation. 
Setting   
23 UK Regional Genetic Centres 1988-2015, and four UK PGD centres 2002-2015 
Participants  
479 couples undergoing prenatal diagnosis (PND) for HD and 305 cycles of pre-
implantation diagnosis (PGD) for HD. 
Main outcome  
Annual rates of PND and PGD for HD. 
Results  
From 1988 – 2015, 479 prenatal diagnoses were performed in the UK for HD, an exclusion 
approach was used in 150 (31%). The annual number of PND for HD has remained in the 
order of 18 cases per year since testing began, a rate of 3.5 per million of UK population. 
Since UK licensing of PGD for HD in 2002, more than 300 cycles of PGD for HD have 
been performed. The annual rate of prenatal diagnosis has remained similar over 27 years, 
despite a steady increase in the use of PGD for HD.  
Conclusions Although increasing number of couples are choosing either direct or exclusion 
PGD to prevent HD in their offspring, both direct and exclusion prenatal diagnosis remain 
important options in a health system where both PGD and PND are state funded. At risk 
couples, should continue to be informed of all options available to them, preferably pre-
pregnancy. 
 
What is already known on this topic 
HD is a late-onset neurogenetic disorder with autosomal dominant inheritance. Whilst not all 
choose to intervene; families at risk have the option of testing an established pregnancy or 
conceiving with preimplantation genetic diagnosis for the disorder. With both methods, 
direct mutation testing or linkage analysis are used to distinguish between high- and low- risk 
conceptions.  
Few studies have reported a long-term, prospective survey of prenatal diagnosis for HD. The 
effect of the availability of PGD on decisions made by families about conventional prenatal 
diagnosis is not known.  
 
What this study adds 
Our study is the longest series of PND and PGD for a neurogenetic disorder. It shows that, 
despite an important increase in the use of PGD, the number of prenatal diagnoses has 
remained stable for 27 years. PGD has not replaced PND, our results suggest a new group of 
patients have been tested. Families at risk of HD in UK should be offered both options pre-
pregnancy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
  HD is an autosomal dominant neurodegenerative disease characterised by cognitive decline, 
movement disorder and frequent psychopathology, leading to death over 10 – 25 years. Onset 
is most often in a person’s 30s - 50s, but may be earlier or later1. Growing-up with an affected 
parent can present a significant psychological burden for those at risk2. Those at risk of HD 
have a number of reproductive options3. Many choose to accept the 50% risk of each child 
being affected, some choose to remain childless, adopt a child or use gamete donors. The 
identification by linkage to the HD locus resulted in the additional option of prenatal 
diagnosis (PND) and termination of affected pregnancies, or increasingly, the possibility of 
pre-implantation genetic diagnosis (PGD) to select mutation-negative embryos conceived by 
in-vitro fertilisation (IVF).  
Pre-symptomatic predictive testing and prenatal diagnosis (PND) in HD serve as paradigms 
for testing in other late-onset genetic neurodegenerative disorders, such as familial early-
onset Alzheimer Disease. Family based linkage studies have been used to offer PND in the 
UK since 1988. Direct mutation testing became possible in 1993 with the discovery that a 
triplet repeat expansion within exon 1 of the gene Huntingtin causes the disease4. Fetal DNA 
samples for PND can be taken using chorionic villus sampling (CVS) from 11 weeks’ 
gestation, and from around 15 weeks by amniocentesis. However, couples with a fetus who 
is at a high risk have can only undergo termination of pregnancy if they are to avoid the birth 
of an affected child. As the majority of individuals at risk of HD choose not to undergo 
predictive testing and it is typically a late onset condition, prenatal testing is not offered for 
information only and couples are carefully counselled around this aspect when making 
reproductive decisions. In preimplantation genetic diagnosis (PGD), couples avoid the need 
for termination through embryo biopsy and genetic testing of pre-implantation embryos 
created using in vitro fertilisation5. PGD for HD was first reported in 19966. 
Some couples who use reproductive technologies to avoid having a child affected by HD 
have undergone predictive testing and know that they carry the HD gene. In such cases, PND 
is typically performed using “direct” testing of the pregnancy for the HD gene mutation. 
Those at risk who wish to avoid passing on the gene but do not wish to find out their own 
HD status, can use “exclusion” or “indirect” testing. DNA markers linked to the HD gene are 
used to establish which grandparent contributed the HD gene passed to the fetus from the at-
risk parent: the affected grandparent or their spouse. If the fetus has not inherited the gene 
from the affected grandparent, this excludes the mutated HD gene in the pregnancy or 
embryo. Exclusion testing, whether applied through PND or PGD, allows the at-risk parent 
to avoid discovery of their genetic risk. However, this means that parents who do not in fact 
have the mutated HD gene, may then terminate an unaffected pregnancy or discard 
unaffected embryos that happens to share the affected grandparental haplotype, as there is a 
50% chance that this haplotype harbours the mutated gene, and a 50% chance that it harbours 
the normal copy.  
In the UK access to PND is overseen by NHS boards/trusts and professional networks, but 
access to PGD is regulated by the Human Fertilisation and Embryology Authority (HFEA). 
Before 1993, prenatal diagnosis for HD was performed using linkage analysis. Both direct 
and exclusion PND have been available in the UK since 1993, free at the point of care through 
NHS public funded healthcare. Direct PGD for HD was licensed in the UK from 2002, and 
exclusion PGD from 2009. NHS funding for direct and exclusion PGD testing for HD is now 
widely available free of charge to couples at risk across the UK who do not already have a 
child and fulfil other NHS funding criteria for PGD. 
With better awareness of reproductive risks and options within families, and increasing 
optimism driven by global research efforts in HD treatment, we hypothesised that the request 
rate for PND might be in decline.  
Data on HD PND has been systematically retrospectively collected from 23 regional genetic 
centres on an annual basis since testing began 27 years ago. Results from the first years 1994-
1998 has been reported7. Here we describe the trends in PND in the UK since inception of 
these services, and compare these with available data on UK PGD uptake. 
 
Methods 
Participants and exposures 
Members of the UK predictive testing consortium retrospectively submitted annual 
anonymous data on prenatal diagnosis uptake from 1987 to 2015, using the same core data 
format for most of that time.  
The number of PGD cycles performed each year for HD reported by Guy’s Hospital, the 
Centre for Reproductive and Genetic Health in London, University College London, the 
Western General Hospital in Edinburgh and the CARE centre in Nottingham.  
Endpoints 
Numbers of cases and the types of test were recorded annually and presented at the annual 
HD Consortium meetings. Additional data were gathered on age, sex of the at-risk partner, 
predictive testing status of the at-risk partner, timing of predictive testing with respect to the 
pregnancy, mode of prenatal diagnosis (direct or exclusion testing), results of prenatal 
diagnosis and pregnancy outcome. Available PGD data included the number of couples 
undergoing treatment and the total number of cycles commenced. 
Statistical analysis 
Analysis of case frequency was performed in all cases. Detailed information was available 
for 411 PND cases. Data were analysed using IBM SPSS version 23, and the Chi squared 
test of proportions. 
Patient involvement  
Patient representatives from the Huntington’s Disease Association attended and contributed 
to discussions about study design and data interpretation at UK predictive testing group 
meetings.  
Results 
From 1988 to 2015, 479 prenatal studies were performed across 23 UK centres. An indirect 
(exclusion) approach was used in 144 (31.2%; Figure 1). Testing rates were low before the 
identification of the gene in 1993, and 1994 saw the highest number of tests requested (37). 
From 1995 – 2015, the rate of PND has remained modest but steady, with a mean of 21 
pregnancies per year being tested.  
Detailed case information was available for 411 PND pregnancies. The at-risk parent was 
female in 51% (Figure 3). The majority of at-risk PND parents had undergone pre-
symptomatic predictive testing (84%), only 15.8% of these predictive tests were performed 
during pregnancy. 
Direct mutation testing was performed in 62.5% of PND, with the exclusion approach being 
used in 37.5 %. The fetus was found to be affected by HD in 53% of direct PND cases, and 
90.2% of these pregnancies underwent termination. The remaining 12 (9.8%) were 
continued, resulting in the parents being aware that the child would one day develop HD. 
Only one HD unaffected pregnancy was reported to have been terminated (Figure 4). Of the 
exclusion tested pregnancies, termination was performed in 87.5% with a high-risk result, 
and the remaining 9 (12.5%) continued. None of the low risk exclusion pregnancies 
underwent termination.  In these 21 continued affected and high-risk pregnancies, the at risk/ 
affected parent was more often the mother (56.3% vs 43.7%), whereas in terminated 
pregnancies the at-risk parent was more often the father (52.9% vs 47.1%) (Figure 5), 
however neither of these differences reached statistical significance (two tailed Chi-square, 
p=0.1616).  
From 2002 to 2015, 305 IVF-PGD cycles were performed in the UK for HD. The annual 
number of PGD cycles has increased steadily over time (Figure 2). 
Discussion 
Principal findings 
PND has been available in the UK since 1988. Other than a peak in the year the HD gene 
was identified, the rate of uptake of PND is modest and has remained remarkably similar 
over more than two decades. The annual number of PGD cycles has steadily increased since 
UK licensing of the procedure in 2002.  
Exclusion testing remains an important option for couples at risk, with around one third of 
PND in the UK using this method. Intriguingly, available data suggests that exclusion testing 
is used more often in PGD (personal communication; data not shown as not available for all 
centres).  
Both at risk men and at-risk women choose PND and PGD. Around 15% of parents are 
symptomatic at the time of reproductive testing.  
During our 27-year study period, the UK population grew from 56.93 million to 65.11 
million, thus the annual rate of HD PND has fallen from to 0.316 per million to 0.276 per 
million. The rate of HD PGD cycles was 0.463 per million in 2015. Taking into account the 
prevalence and incidence of HD, we have estimated that the order of magnitude for the uptake 
of PND and PGD in 2015 was  at least 3.4% of  at risk pregnancies(see Supplementary Info). 
Despite the rising uptake of PGD for HD, the vast majority of UK pregnancies at risk of HD 
continued to remain untested. 
Access to PND and PGD funding varies worldwide. In the UK, both PND and PGD for HD 
is fully publicly funded for couples by the NHS and is generally co-ordinated through Genetic 
Regional Centres. Although in some areas (e.g. Scotland) PGD access is limited to couples 
without a child, we propose that this data indicate couples’ behaviour in an environment 
where at least some real choice is available. 
Strengths and limitations of the data 
Here we report on more than 27 years’ use of prenatal and preimplantation diagnosis across  
the UK. This is by far the longest longitudinal study of HD reproductive choices worldwide, 
and demonstrates, on a national scale, the impact reproductive technologies like PND and 
PGD.  
Although testing rates have been captured reliably through the course of the study, detailed 
data for 12% of cases is missing due to the challenges of data collection in a nationwide study 
over three decades and without specific funding. Only minimal and anonymous data were 
collected, to maintain participation, but PND rates may be slightly under reported. PGD data 
werewas obtained directly from all UK centres currently offering PGD. The number of PGD 
cycles are not equivalent to PND rates as they do not always result in a clinical pregnancy. 
The likely level of under ascertainment does not alter our conclusions.  
Comparison with previous studies 
As genetic diagnosis of HD is only provided in the UK by the NHS (I am uncertain this is 
the case as I know of people diagnosed through private neurologists and patients who have 
seen private geneticist about prenatal) our data represent a true nationwide picture, in contrast 
to other countries where a market in private genetic testing limits data access. A small part 
of UK cases has been reported in a European context9; but only a few studies have reported 
national experience of prenatal diagnosis for HD, with reports from Canada10, Australia11 
and the Netherlands12 but these reports did not capture the transition to PGD. 
Van Rijj et al.12 reported a series of 126 Dutch HD prenatal diagnoses. 82% of affected 
pregnancies in that series resulted in termination, in contrast to 90% in our UK series. They 
estimated that in the Netherlands 22% of at risk couples used PND when pregnant. An 
adjunct paper analysing the uptake of PGD found that couples opting for PGD after 
pregnancy were more likely to have terminated a previous affected pregnancy than those 
undergoing PND alone (87% vs 55%)13 .   
. In the present study, other factors may play a role.   In the UK, patient access to both PND 
& PGD is covered by the NHS; although the support for PGD is more limited.  NHS funding 
for PGD is limited to 3 cycles or one successful pregnancy and, if couples had an existing 
child together that is unaffected or status unknown they would be unable to access PGD on 
the NHS. In addition, some people may feel the option of PGD in the UK is restricted due to 
the geographical location of the few centres that are licenced to offer NHS funded PGD. In 
the Netherlands, ‘non-disclosure’ PGD is banned by law, so that those who wish to use this 
approach must travel to a different country such as Belgium, while in UK the majority of 
PGD cycles are exclusion diagnoses.  
Regional differences impact the use of prenatal/preimplantation diagnosis. There is no 
European registry of prenatal diagnosis for genetic disorders, but the European Society of 
Human Reproduction (ESHRE) maintains a PGD registry. The latest report from 2010 found 
that, of 1574 cycles performed for monogenic disorders, 158 (10%) were for HD. Across the 
ESHRE dataset, the pregnancy rate for PGD was 22%; 2 of 10 couples for whom embryo 
transfer is performed are achieving a pregnancy14. In the UK, HD has become the most 
common indication for monogenic PGD, and pregnancy rates are 34% per cycle, with a live 
birth rate of 23% for fresh embryo transfer and 18% for frozen from 1999-201215. The latest 
data available from HFEA reported a 25.6% live birth per initiated cycle for 201316.  In the 
UK, there are restrictions for NHS funding of PGD cycles including the female partner’s age, 
body mass index, the smoking status, alcohol and illegal drug use of both partners. NHS 
funding criteria are limited to couples who do not have an unaffected child. This excludes 
those who have had successful  PGD/PND previously but also those who have chosen not to 
have a test and therefore do not know the genetic statues of their current child. Therefore, 
PGD is not freely available to all couples at risk. 
Clinical and research implications 
In choosing between PND and PGD couples balance personal, ethical, cultural and health 
issues. Many couples consider the concept of PGD as more attractive than PND when 
planning a future pregnancy, as it avoids termination of affected pregnancies and the 
procedure-associated loss of a normal pregnancy. However, the risks and stresses of IVF also 
bring their own burdens, coupled with a lower chance of a successful pregnancy outcome17. 
IVF and PGD put extra risks in a woman compared to those interested in prenatal diagnosis, 
amniocentesis or chorionic villi sampling, that generate primary a pregnancy loss risk. 
Patterns of CVS and amniocentesis usage are changing rapidly with the advent of non-
invasive prenatal testing (NIPT) for screening Down syndrome and other aneuploidies and 
non-invasive prenatal diagnosis (NIPD) for some de novo paternal monogenic disorders 
using fetal free DNA. A case of NIPD for HD was recently reported18. Although Van den 
Oever18 demonstrated the proof of principle that free fetal DNA can be used for the diagnosis 
of HD, the intrinsic technical challenges of sequencing for a triplet repeat disorder means 
that this technique is not available in the UK and majority of countries. A linkage-based 
approach may be preferred, as often used in PGD for HD and other monogenic disorders. 
Funding is not currently available for NIPD in the UK. 
Further studies of the social and health economic consequences of PND and PGD are 
required to understand the full effect of these reproductive technologies for the burden of 
disease in families affected by HD. Our data suggest that a long-term policy of making 
reproductive technologies available on a population basis free at the point of care has led to 
a significant reduction in HD births in the UK but the principal motivation for service 
provision has to remain the wish to support patients and families in facing and coping with 
this disease. Families with HD require support to face the challenges of this disease and to 
lead lives, as individuals and families, that are as full and rewarding as can be achieved.  
The cost of PND is around £210 plus clinic costs and of PGD is around £12,000 (only 
compared with an IVF cycle costs of around £7,500). These costs are easily outweighed by 
the lifetime medical and social care costs of HD that may be averted by the decisions to avoid 
having a child who may be affected. The UK health care funding model offers couples the 
opportunity to choose between PND and PGD, and thus we propose that our results reflect 
couples’ wishes for testing when largely unencumbered by financial considerations.  
Conclusions  
This is the longest running study reporting national rates of prenatal and preimplantation 
diagnosis for a neurogenetic disorder. Prenatal diagnosis, by both direct and exclusion test 
methods, is as popular in the UK now as a generation ago. The rate of pre-implantation 
genetic diagnosis for HD is rising, with many couples seeking exclusion testing. Thus, many 
more at-risk couples are seeking to give birth only to children whom they know will not be 
affected by HD compared with 20 years ago. Couples including one partner at risk of HD 
should be offered non-directive information about the reproductive options, pre-pregnancy 
advice and access to both direct and exclusion PND and PGD. 
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Figures Legends 
 
Figure 1. Number of prenatal diagnosis cases for HD in UK, in the period of the study (1988-
2015). Red bars refer to direct testing and blue bars to exclusion testing. 
Figure 2. Comparison of prenatal diagnosis (PND) vs preimplantation genetic diagnosis 
(PGD) since 2002. Red line refers to PND direct testing, blue line exclusion testing, black 
line the total, and dotted line the trend during the period. Green line displays the number of 
PGD-in vitro fertilisation cycles. 
Figure 3. Type of testing in the affected parent. Yellow shows patients with pre-symptomatic 
testing, green symptomatic (diagnostic) and blue not tested. 
Figure 4. Follow-up of pregnancies with prenatal diagnosis. Top. Indirect testing.  Bottom. 
Direct testing. Blue bar shows number of terminated pregnancies and green continued 
pregnancies. 
Figure 5. Results of follow-up of pregnancies with prenatal diagnosis according the sex of 
the parent at risk.  Blue bar shows number of terminated pregnancies and green continued 
pregnancies. 
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Supplementary Info 
Estimation of PND/PGD uptake in 2015. 
An estimate of the percentage of HD at risk births undergoing prenatal diagnosis or PGD was 
estimated based upon: 
1) The denominator number of 12-week pregnancies at 50% risk: 
The UK population in 2015 = 65,110,000 
Assuming a prevalence of 10 / 100,000 gives 6511 cases 
Assuming a disease duration of 18.8 years gives an incidence of 346.3 per year in the UK 
  
A distribution for the age of onset was assumed as reported inHarper & Newcombe 1992.1  
).  Standard life tables were used to estimate that there would need to be 365.3 births per year to 
maintain this incidence. Using a pregnancy loss rate of 4 % at 12 weeks (Avalos  et al 2012)  it 
would require 380.5  twelve week embryos, and therefore 761.1 embryos were at 50% risk 
 
  
2) The numerator for the prenatal tests: 
The number of direct tests is 10. The number of exclusion tests is 7, but half of these 
would have been unnecessary if the parents had all been tested - so we have 3.5 tests of 
pregnancies at 50% risk. So, the total number of prenatal tests is 13.5. 
  
3) The numerator for the PGD tests: 
 
the numerator for direct PGD tests is 36 / 80 (based on PGD data collected for this study) 
x 52 PGD tests = 23.4 tests. 
  
The numerator for the exclusion PGD tests is 44 / 80 x 52 PGD tests = 28.6 tests (which 
means that 28.6 / 2 = 14.3 tests were for pregnancies at 50% risk). 
 
The total number of PGD tests at 50% risk was  23.4 =14.3 =37.7 
 We could not assume that those having PGD would have had pre-natal diagnosis so the number 
of PGD cases was reduced by 1/3 based on an approximation of the success rate of PGD per cycle 
started at Guy’s Hospital (Lashwood A personal communication).  
 
This gives a numerator for the PGD cycles of 12.6 
 
 
Overall, the testing proportion is thus around (13.5 +12.6) / 761.1 =3.4 
We cannot assume that all those undertaking a pregnancy were aware of their risk.  There are no 
estimates for this but, if half of those undertaking a pregnancy were aware of their risk, the uptake 
would be 6.8%. If estimates of those aware of their risk were closer to 25% or 75% then the uptake 
would be of the order of magnitude of 13.6% and 4.5% respectively. 
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